Screener
Ultragenyx Pharmaceutical RARE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Based on trailing twelve months.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's EBITDA margin?
- Ultragenyx Pharmaceutical (RARE) reported EBITDA margin of -69% in Q2 2026.
- How has Ultragenyx Pharmaceutical's EBITDA margin changed year-over-year?
- Ultragenyx Pharmaceutical's EBITDA margin increased by 10.2% year-over-year, from -76.9% to -69%.
- What is the long-term trend for Ultragenyx Pharmaceutical's EBITDA margin?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's EBITDA margin has grown at a -8.7% compound annual growth rate (CAGR), from -117.3% to -74.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Ultragenyx Pharmaceutical's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude